ABSORB Post-Approval Clinical Study

Trial Profile

ABSORB Post-Approval Clinical Study

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Ischaemic heart disorders
  • Focus Adverse reactions
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 09 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 02 Aug 2017 Planned number of patients changed from 3000 to 2000.
    • 02 Aug 2017 Planned initiation date changed from 1 Nov 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top